ARCHIVED: Appendix 4: The Management of the National Antiviral Stockpile: Options Report - Comparison of international stockpiling tends

**Appendix 4: Comparison of International Stockpiling Trends**
Country (population)	Size and composition of stockpile	Uses	Comment
Canada (33M)	~ 25% of population NAS: 50.7 M doses oseltamivir 5 M doses zanamivir plus other federal and PT stockpiles (~80M total)	Early treatment, Rapid containment Outbreak control; Post-exposure prophylaxis in Phase 4/5	Private stockpiles may be present for pre-exposure prophylaxis
United States (304M)	25% of population (Goal 35%) almost all oseltamivir	Early treatment, rapid containment (prophylaxis to be covered by private stockpiling)	Endorsing private stockpiling; has well-established shelf-life extension program
United Kingdom (61M)	25% population; recent commitment to increase to 50% population (32.8M) - two thirds oseltamivir - one third zanamivir	Early treatment – enough for severe pandemic and small amount for pre exposure prophylaxis	Post-exposure prophylaxis in households under consideration; looking at alternatives for expiring stock
France (62M)	50% of population (may share with other EU countries) - 240 M doses oseltamivir - 90 M doses zanamivir	Early treatment; pre-exposure prophylaxis in Phase 4/5	Stock began to expire in 2008; looking at shelf-life extension
Japan (127M)	23% of population, target is 45% (may share with Thailand and other Asian countries) - 240M doses oseltamivir - 90 M doses zanamivir	Largely early treatment	Has a shelf-life extension program

Source: Global Health Security Action Group Pandemic Influenza Planning and Preparedness Survey, 2008

Page details